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Abstract
Background: The motor protein myosin Va plays an important role in the trafficking of intracellular vesicles. Mutation of the
Myo5a gene causes Griscelli syndrome type 1 in humans and the dilute phenotype in mice, which are both characterised by
pigment dilution and neurological defects as a result of impaired vesicle transport in melanocytes and neuroendocrine cells.
The role of myosin Va in platelets is currently unknown. Rab27 has been shown to be associated with myosin Va cargo
vesicles and is known to be important in platelet dense granule biogenesis and secretion, a crucial event in thrombus
formation. Therefore, we hypothesised that myosin Va may regulate granule secretion or formation in platelets.
Methodology/Principal Findings: Platelet function was studied in vitro using a novel Myo5a gene deletion mouse model.
Myo5a2/2 platelets were devoid of myosin Va, as determined by immunoblotting, and exhibited normal expression of
surface markers. We assessed dense granule, a-granule and lysosomal secretion, integrin aIIbb3 activation, Ca
2+ signalling,
and spreading on fibrinogen in response to collagen-related peptide or the PAR4 agonist, AYPGKF in washed mouse
platelets lacking myosin Va or wild-type platelets. Surprisingly, Myo5a2/2 platelets showed no significant functional defects
in these responses, or in the numbers of dense and a-granules expressed.
Conclusion: Despite the importance of myosin Va in vesicle transport in other cells, our data demonstrate this motor
protein has no non-redundant role in the secretion of dense and a-granules or other functional responses in platelets.
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Introduction
The unconventional, non-muscle, class V myosins play an
important role in the transport of intracellular vesicles along actin
filaments to membrane docking sites [1]. The isoform myosin Va
has been shown to be crucial in the trafficking of melanosomes in
melanocytes [2] and in the secretion of granules in neuroendocrine
cells [3]. Mutations in the Myo5a gene lead to Griscelli syndrome
type 1 in humans, a rare inherited autosomal recessive disorder
characterised by hypopigmentation and neurological impairment
[4]. In mice, myosin Va mutations result in the dilute phenotype
with a lighter coat colour and lethal neurological defects [5].
A variety of proteins involved in the regulation of granule
transport has been described to interact with myosin Va. In
melanocytes, the cargo-carrying C-terminal tail of myosin Va
binds to the exophilin melanophilin [6,7] which in turn interacts
with Rab27 [8], a GTP-binding protein of the Ras superfamily.
Knockout of Rab27a/b in mice and Griscelli syndrome type 2 in
humans, caused by mutation of the Rab27a gene, both show
platelet defects resulting in increased bleeding times and a
reduction in the number of dense granules, indicating that
Rab27 is a key player in platelet dense granule biogenesis and
secretion [9–12].
The secretion of intracellular granules from platelets is essential
in the process of thrombosis. Upon activation, platelets release a
wide array of mediators from their dense and a-granules [13].
Dense granules contain pro-aggregating factors, which sustain and
enhance initial platelet responses. In addition to molecules
involved in thrombus formation, a-granules also store a range of
proteins and receptors involved in other patho-physiological
processes, such as inflammation. As Rab27 is known to be
associated with myosin Va cargo vesicles and myosin Va is highly
expressed in both human and mouse platelets [14], it is of great
interest to determine the role of this motor protein in platelet
granule secretion and formation.
In the present study, we used a novel targeted Myo5a gene
deletion mouse model, which is non-lethal and shows no overt
neurological phenotype. As shown by immunoblotting, myosin Va
was undetectable in platelets from Myo5a2/2 mice. Levels of
surface proteins and granule counts were normal in Myo5a2/2
platelets. Contrary to our expectations, loss of myosin Va resulted
in normal agonist-induced dense and a-granule secretion and
unchanged numbers of dense and a-granules expressed. Further-
more, integrin aIIbb3 activation, Ca
2+ signalling, and spreading on
fibrinogen were not affected in Myo5a2/2 platelets. These results
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establish that myosin Va is not required for most platelet
responses, including dense and a-granule secretion.
Methods
Materials
The myosin Va antibody (#3402) was from Cell Signaling
Technology (Danvers, MA, USA). The myosin Vb antibody (18),
the myosin Vc antibody (Y-19), and the GAPDH antibody (6C5)
were obtained from Santa Cruz Biotechnology (Santa Cruz, CA,
USA). The myosin VI antibody (ABT42) was from Millipore
(Temecula, CA, USA). Horseradish peroxidase (HRP)-conjugated
donkey anti-rabbit, anti-mouse and anti-goat secondary antibodies
were from Jackson ImmunoResearch Laboratories (Newmarket,
UK). FITC-P-selectin and PE-JON/A antibodies were from
Emfret Analytics (Eibelstadt, Germany). FITC-LAMP1 (1D4B)
antibody was from Abcam (Cambridge, UK). NuPAGE LDS
sample buffer was obtained from Invitrogen (Carlsbad, CA, USA).
106 blocking buffer and TRITC-phalloidin were from Sigma-
Aldrich (Poole, UK). Fura-PE3 was from Teflabs (Austin, TX,
USA). Luciferin-luciferase was from Chronolog (Labmedics,
Stockport, UK). AYPGKF-NH2 (PAR4 activating peptide) was
from Bachem (Weil-am-Rhein, Germany). CRP (cross-linked
collagen-related peptide) was synthesized by Prof Richard Farn-
dale (Department of Biochemistry, University of Cambridge, UK).
Mouse platelet preparation
A colony of Myo5a2/2 mice was obtained from the Wellcome
Trust Sanger Institute (Cambridge, UK), which were mated with
C57/Bl6j mice (Charles River, UK) to generate Myo5a+/2. These
mice were crossed to generate Myo5a2/2 mice and littermate
Myo5a+/+ mice, which were used as control (wild-type, WT). Use
of mouse platelets was approved by local research committee at
the University of Bristol, UK, and mice were bred for this purpose
under UK Home Office Licence PPL30/2908 held by Alastair W.
Poole. Blood was drawn and washed platelets were prepared as
described previously [15]. In brief, blood was drawn by cardiac
puncture under terminal anesthesia into sodium citrate (4%; 1:10
v/v). Blood was diluted with modified Tyrode’s-HEPES buffer
(134 mM NaCl, 2.9 mM KCl, 20 mM HEPES, 5 mM glucose,
and 1 mMMgCl2, pH 7.3) and centrifuged at 180 g for 6 minutes
at room temperature. Platelet-rich plasma was removed, and
platelets were isolated by centrifugation at 550 g for 6 minutes in
the presence of PGE1 (140 nM) and apyrase (0.02 U/ml). Pelleted
platelets were resuspended to the required density in modified
Tyrode’s-HEPES buffer and rested for 30 minutes at 37uC in the
presence of 0.02 U/ml apyrase prior to stimulation. No indo-
methacin or other cyclooxygenase inhibitors were added during
platelet preparation. Unless otherwise indicated, 1 mM CaCl2 was
added immediately prior to stimulation.
Electrophoresis and Western blotting
Washed platelets (26108/mL) were lysed in NuPAGE LDS
sample buffer which was supplemented with 50 mM dithiothreitol.
Samples were separated by electrophoresis on 6% Bis-Tris
polyacrylamide gels. Proteins were then transferred to polyviny-
lidene difluoride membranes which were blocked with 16
blocking buffer and probed with specific primary and HRP-
conjugated secondary antibodies. Proteins were detected using
ECL reagents.
Subcellular morphology
Subcellular morphology of WT and Myo5a2/2 platelets was
analysed by transmission electron microscopy (TEM). Platelet-rich
plasma was collected and spun at 590 g for 5 minutes. Supernatant
was removed from the platelet pellet, and the pellet was fixed in
2.5% glutaraldehyde in 0.1 M phosphate buffer (PB) (pH 7.4).
The pellet was washed in PB and then incubated in 1% osmium
tetroxide in PB for 30 minutes. After washing in PB and deionized
water, the pellet was incubated in 3% uranyl acetate in deionized
water for 30 minutes. After washing with deionized water, the
pellet was dehydrated in a graded series of increasing amounts of
ethanol (70%, 80%, 90%, 96%, 100%, and 100%, with each step
lasting for 10 minutes). After removal of the 100% ethanol, the
pellet was incubated with pure Epon for 2 hours at room
temperature. Thereafter, the Epon was replaced with fresh Epon,
and this was hardened overnight in a 60uC oven. Ultrathin
counterstained sections were imaged on a Philips CM100
equipped with a side-mount MegaView III camera (Olympus
Soft Imaging Solutions).
To determine the dense-granule and a-granule content, total
numbers of granules in equivalent-sized fields of view were
counted. For each genotype, 10 randomly chosen fields of view
were examined. All microscopic images were taken at the same
magnification, and the number of cells per field of view was
equivalent between WT and Myo5a2/2 preparations. The number
of dense granules and a-granules is expressed as the mean number
per platelet slice. This approach allows the number of each
granule type to be compared between WT and Myo5a2/2
platelets, although since individual thin sections of platelets are
imaged, the number of granules seen is substantially fewer than the
total number of granules in individual platelets.
Dense granule secretion
The release of ATP from dense granule release was assessed
luminometrically, as previously described [15]. Briefly, platelets
were incubated with Chrono-Lume luciferase-luciferin reagent
before stimulation with the indicated concentration of agonist.
ATP secretion was measured as an increase in luminescence.
Integrin aIIbb3 activation and a-granule secretion
Washed platelets (56107/mL; 32 mL) were incubated fluores-
cein isothiocyanate (FITC)-labelled anti-P-selectin antibody, phy-
coerythrin (PE)-labelled JON/A antibody (4 mL of each), and
agonist (4 mL; 1:10 dilution) for 10 min under non-stirring
conditions. Platelets were then fixed with paraformaldehyde
(2%). Two-colour analysis was conducted by flow cytometry on
a FACSCalibur flow cytometer (BD Biosciences), using CellQuest
version 3.1f software (BD Biosciences). The platelet population was
identified by forward and side scatter profile.
To assess the timecourse of a-granule secretion, platelets were
stimulated for the indicated time with AYPGKF (300 mM) prior to
fixation. FITC-labelled anti-P-selectin was added for the final 30 s
of stimulation.
Lysosome secretion
Washed platelets (56107/mL; 36 mL) were incubated FITC-
labelled anti-LAMP1 antibody (4 mL), and agonist (4 mL; 1:10
dilution) for 10 min under non-stirring conditions. Platelets were
then fixed with paraformaldehyde (2%). FITC fluorescence was
analysed by FACS analysis as above.
Ca2+ signalling
Changes in cytosolic [Ca2+]i were measured by spectrofluo-
rometry in washed suspensions of platelets (16108/mL) loaded
with the Ca2+-senstive dye, Fura-PE3, as described previously
[16]. Platelets were stimulated at 37uC with continuous stirring.
Myosin Va in Platelets
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Figure 1. Phenotyping of Myo5a2/2 mice and platelets. (A) Schematic of the targeting vector used to disrupt the Myo5a genomic locus
between exons 2 and 3. The cassette contains the lacZ reporter gene, the neomycin (neo) resistance gene, and a polyadenylate (pA) sequence which
causes transcription termination. Flp recombination target (FRT) sites are included on either side of the vector along with a loxP site at the 39 end. In
(B), the difference in coat pigmentation of Myo5a2/2 mice compared to wild-type (WT) is shown. (C) Offspring ratios of knockouts (2/2),
heterozygotes (+/2) and wild-types (+/+) from heterozygote breeding pairs were compared from 162 mice. Blood platelet count (D) and mean
Myosin Va in Platelets
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Fura-PE3 was excited alternately at 340 nm and 380 nm, and
fluorescence emission detected at 510 nm. Fluorescence signals
were corrected for autofluorescence and calibrated in terms of
[Ca2+]i as previously described [16]. Ionomycin (1 mM) was added
in the presence of the calcium chelator EGTA (1 mM).
Alternatively, platelets were stimulated with the indicated concen-
trations of CRP in the presence of 1 mM CaCl2.
Platelet spreading
Coverslips were coated with fibrinogen (100 mg/ml). Washed
platelets (26107/mL) were dispensed onto the coverslip for 1 hr.
Where indicated, platelets were stimulated with AYPGKF
(300 mM) for 1 min prior to adhesion. Adherent platelets were
fixed with paraformaldehyde (4%), permeabilised with Triton X-
100, and stained with TRITC-phalloidin. Adhesion and spreading
of platelets was observed by fluorescence microscopy using a
cooled CCD camera attached to a Leica DM IRB inverted
epifluorescence microscope with a 636 objective. Ten images
were taken in different random parts of the coverslip area and
analysed using ImageJ software. Platelets were scored as being
completely unspread with no filopodia (‘‘no spreading’’), having
filopodia, having both filopodia and partial lamellipodia (‘‘some
spreading’’), or having a full lamellipodium (‘‘full spreading’’) and
expressed as a proportion of the total number of platelets in the
platelet volume (E) were measured in Myo5a2/2 and wild-type (WT) mice (n = 18 and 25, respectively). (F) Immunoblots showing the expression of
myosin Va protein in lysates from human, wild-type (WT) mouse and Myo5a2/2mouse platelets. Note the absence of a detectable myosin Va band in
the knockout platelets. (G) Platelet surface levels of the indicated proteins were analysed by flow cytometry. Data (mean +/2 SEM, n = 4–7) are mean
fluorescence intensity levels.
doi:10.1371/journal.pone.0053239.g001
Figure 2. Myo5a2/2 platelets have normal subcellular morphology. (A) TEM images (48006, scale bar: 1 mM) show representative images of
WT and Myo5a2/2 mouse platelets (n = 4). Black arrows: dense granules. White arrows: a-granules. (B) Platelet dense and a-granules were quantified
per field of view (10 fields of view per preparation) and data (mean +/2 SEM, n = 4) are shown as the number of granules per platelet visible in the
section. This number is for comparison between genotypes only, as granules above or below the thin section plane will not be visible, and so the
number will be an underestimate of the total granule count per platelet.
doi:10.1371/journal.pone.0053239.g002
Myosin Va in Platelets
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image. The proportions of each morphology in each of the ten
images were then averaged. This analysis was performed
separately on platelets from 3 WT mice and 3 Myo5a2/2 mice.
Statistics
Where presented, mean data are given 6 SEM. Statistical
significance was determined by 2-way ANOVA with Bonferroni
post-test, performing using Prism 4.0 (GraphPad Software).
P,0.05 was considered significant.
Results and Discussion
Selective depletion of myosin Va from mouse platelets
To evaluate the function of myosin Va in platelets, Myo5a2/2
mice were obtained from Wellcome Trust Sangar Institute
(Cambridge, UK), in which the gene encoding this protein (Myo5a)
had been disrupted by homologous recombination in embryonic
stem cells, and the cells were used to generate gene-targeted mice
by standard techniques (Fig. 1A). Myo5a2/2 mice were viable and
healthy, but showed a lighter grey coat colour compared to wild-
type controls (Fig. 1B), similar to the hypopigmentation which is
seen in the dilute mice. This suggests that our mice are likely to
have a similar defect in Myo5a-dependent melanosome trafficking
to dilute mice [5]. Mice were not obtained in their expected
Mendelian ratios (Fig. 1C). Of 130 offspring genotyped, 48 were
wild-type (37.5%), 63 were heterozygous (49.2%) and only 17 were
Myo5a2/2 (13.3%). Low generation of Myo5a2/2 mice was seen in
both male and female offspring. Myo5a2/2 mice exhibited normal
platelet count and mean platelet volume (Fig. 1D and E). Other
haematological parameters, specifically the red blood cell count,
haematocrit, mean corpuscular volume and white blood cell
count, were also within the normal range (data not shown).
As demonstrated by immunoblotting, myosin Va (207 kDa) was
not detected in Myo5a2/2 platelets, whereas it was expressed in
wild-type mouse platelets as well as in human platelets (Fig. 1F).
Myo5a2/2 platelets had normal levels of surface-expressed CD41,
glycoprotein (GP) VI and GPIb (Fig. 1G). Thus, Myo5a2/2
platelets provided us an ideal opportunity to study platelet function
in the selective absence of myosin Va.
Platelet granule biogenesis and secretion are unaffected
by loss of myosin Va
Since Rab27 regulates dense granule formation and secretion in
platelets [10] and has been shown to interact with myosin Va in
melanocytes [8], we investigated whether myosin Va is also
involved in platelet dense granule formation and secretion.
Subcellular morphology of platelets from WT and Myo5a2/2
mice was examined by TEM (Fig. 2A), and visible granules
counted (and normalized to the number of platelets in the field of
view; Fig. 2B). Both dense and a-granule counts in each thin
section were similar to wild-type, suggesting that myosin Va is not
involved in platelet granule biogenesis.
Dense granule secretion of ATP, monitored by luminometry,
was stimulated by a range of concentrations of the GPVI agonist,
collagen-related peptide (CRP) or the thrombin receptor PAR4
agonist, AYPGKF. However, no difference in ATP secretion was
observed between wild-type and Myo5a2/2 platelets at any
concentration tested (Fig. 3A). This indicates that myosin Va is
not required for the secretion of dense granule content.
Next, we addressed whether myosin Va has a role in a-granule
secretion. By flow cytometric analysis, P-selectin expression on the
platelet surface was assessed. P-selectin surface expression induced
by various concentrations of CRP and AYPGKF was not
significantly affected in Myo5a2/2 platelets compared to wild-type
(Fig. 3B), suggesting that myosin Va is not required also for a-
granule secretion in platelets. In addition, analysis of the time
course of a-granule secretion indicated that the rate of P-selectin
expression was not different between wild-type and Myo5a2/2
platelets (Fig. 3C).
Finally, we investigated whether myosin Va regulates lysosome
secretion by assessing agonist-induced surface expression of
LAMP1, which correlates with lysosomal enzyme release. Platelet
activation induced an increase in surface LAMP1. This was not
different between WT and Myo5a2/2 platelets, indicating that
lysosome secretion is not affected by loss of myosin Va. Taken
together, these data show that myosin Va has no non-redundant
role in granule secretion in mouse platelets.
There are several possible explanations for these data. It is
possible that myosin Va genuinely plays no role in granule
Figure 3. Loss of myosin Va does not affect platelet dense, a-granule or lysosome secretion. Wild-type and Myo5a2/2 platelets were
stimulated with the indicated concentrations of collagen-related peptide (CRP) and the PAR4 agonist AYPGKF. (A) ATP release from dense granules
was assessed luminometrically. Data (mean +/2 SEM, n = 4–7) are levels of released ATP. (B) P-selectin expression as a result of a-granule secretion
was measured by flow cytometry, after agonist stimulation for 10 min. Data (mean +/2 SEM, n = 5–7) are shown as fold increase over basal. (C) Time
course of P-selectin expression induced by AYPGKF (300 mM). Data (mean +/2 SEM, n = 4) are levels of FITC fluorescence intensity. (D) Lysosome
secretion, as assessed by LAMP1 flow cytometry, was determined after agonist stimulation for 10 min. Data (mean +/2 SEM, n = 4) are shown as fold
increase over basal.
doi:10.1371/journal.pone.0053239.g003
Figure 4. No enhanced expression of myosin Vb, Vc and VI in Myo5a2/2 platelets. Immunoblots showing the expression of myosin Vb, Vc,
and VI in lysates from human, wild-type mouse (WT) and Myo5a2/2 mouse platelets. Lysates from mouse liver, pancreas or kidney were used as
positive controls for myosin Vb, Vc, and VI, respectively. GAPDH served as loading control. Images shown are representative of three independent
experiments.
doi:10.1371/journal.pone.0053239.g004
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Figure 5. No difference in integrin aIIbb3 activation in myosin Va-deficient platelets. Wild-type and Myo5a
2/2 mouse platelets were
stimulated for 10 min with the indicated concentrations of collagen-related peptide (CRP) and the PAR4 agonist AYPGKF. JON/A binding to the
activated form of integrin aIIbb3 was measured by flow cytometry. Data (mean +/2 SEM, n= 5) are shown as fold increase over basal.
doi:10.1371/journal.pone.0053239.g005
Figure 6. Normal Ca2+ signalling in Myo5a2/2 platelets. Wild-type and Myo5a2/2 platelets were loaded with the Ca2+-sensitive dye Fura-PE3.
(A) Ionomycin (1 mM) was added in presence of the calcium chelator EGTA (200 mM). (B) Platelets were stimulated with the indicated concentrations
of CRP in the presence of 1 mM CaCl2. The left hand panels show representative traces (n = 3). Data in the right hand panels (mean +/2 SEM, n = 3)
are expressed as area under the curve (AUC).
doi:10.1371/journal.pone.0053239.g006
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secretion in platelets, despite a role for Rab27. This could reflect
the small size of the platelet, and its extensive plasma membrane-
associated target membrane system, the open canalicular system.
This is comprised of multiple invaginations of the membrane,
forming target sites for fusion of exocytotic vesicles throughout the
cell. Effectively, this may mean that the majority of secretory
vesicles may already be in a primed and docked position, and that
there is no need for myosin-dependent trafficking. It might
however be assumed that vesicles require trafficking to platelets
within the megakaryocyte, and therefore that myosins may be
required for this step. However, data from Fig. 2A and 2B show
that these platelets contain normal numbers of both a-granules
Figure 7. Loss of myosin Va does not affect platelet spreading on fibrinogen. Wild-type and Myo5a2/2 mouse platelets were dispensed
onto fibrinogen-coated coverslips for 1 h. Where indicated, platelets were stimulated with the PAR4 agonist AYPGKF (300 mM) for 1 min prior to
adhesion. Cells were stained with TRITC-phalloidin. In (A), representative images are shown (n= 3). (B) Platelet morphological subtypes were counted
and fractions (mean +/2 SEM, n = 3) were calculated.
doi:10.1371/journal.pone.0053239.g007
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and dense granules and therefore that myosin Va expression is also
not required for normal trafficking and packaging of secretory
granules into platelets at the level of the megakaryocyte. It is likely
that, for this role, myosin II is the predominant motor protein
involved [17,18].
On the other hand, it is also possible that other related myosins
are expressed or over-expressed in the Myo5a2/2 platelet, and that
redundancy of function with these myosins is such that there is no
observable phenotype in the single Myo5a2/2 mouse. Myosin Vb
is involved actin-dependent vesicle transport and plasma mem-
brane recycling in various cells, including neurons and oocytes
[19–21]. Myosin Vc localises with membrane compartments
involved in transferrin trafficking in epithelial cells [22] and has
been shown to function as a molecular motor driving secretory
granule transport in lacrimal gland acinar cells and the MCF-7 cell
line [23,24]. To examine the expression of myosin Vb, Vc, and VI,
we immunoblotted for these proteins in human, wild-type, and
Myo5a2/2 platelets (Fig. 4). Myosin Vb and Vc could not be
detected in any platelet sample, suggesting that the absence of a
platelet defect in myosin Va-deficient mice is not a consequence of
normal expression or compensatory upregulation of myosin Vb or
Vc. The absence of these proteins is consistent with mRNA
analysis of human and mouse platelets [14].
Recently, it has been found that myosin VI regulates fusion
pores formed between secretory vesicles and the plasma
membrane [25]. In contrast to myosin Vb and Vc, myosin VI
was present in human, wild-type and Myo5a2/2 platelets. There
was no upregulation of myosin VI detected in myosin Va-deficient
platelets, suggesting that its expression does not change in the
absence of myosin Va. However, the presence of myosin VI in
platelets, and its recently reported role in exocytosis, provides the
possibility that this protein is involved in platelet granule secretion,
and that there may be redundancy of function between this motor
protein and myosin Va in the control of granule secretion. This
may be more important in mouse platelets than in human
platelets, as mRNA analysis indicates a greater abundance of myo6
mRNA in mouse platelets [14]. The possible role of myosin VI in
mouse platelet exocytosis deserves further attention.
Myo5a2/2 platelets show normal integrin aIIbb3
activation, Ca2+ signalling and spreading
It was important also to investigate whether myosin Va plays a
role in other platelet responses. Integrin aIIbb3 activation was
assessed by using the activation-specific antibody, Jon/A. CRP or
AYPGKF induced integrin aIIbb3 activation in wild-type and
Myo5a2/2 platelets with no significant differences over a range of
concentrations of agonists (Fig. 5).
Myosin Va transports extensions of the ER into dendritic spines
of Purkinje neurons, forming a local Ca2+ store that is required for
local Ca2+ release [26]. We tested therefore whether myosin Va
also transports Ca2+ stores into platelets during thrombopoiesis.
Mouse platelets were loaded with the Ca2+-sensitive dye, Fura-
PE3. Rapid depletion of the intracellular Ca2+ stores by ionomycin
produced a transient increase in [Ca2+]i that was not significantly
different in Myo5a2/2 platelets (Fig. 6A). Furthermore, Ca2+
signals in response to a range of concentrations of CRP were not
significantly altered (Fig. 6B). These data suggest that myosin Va is
not required to transport intracellular Ca2+ stores into platelets,
since the stores are equivalently loaded with releasable calcium,
and is not involved in agonist-induced Ca2+ signalling in platelets.
Finally, we analysed whether loss of myosin Va affects platelet
spreading on a fibrinogen-coated surface. Myo5a2/2 platelets did
not show a difference in spreading on this surface whether in
presence or absence of stimulation with AYPGKF (Fig. 7A).
Morphological analysis also did not reveal any difference in
subtype fractions (no spreading, filopodial, some spreading or full
spreading) between myosin Va-deficient and wild-type platelets
(Fig. 7B).
We conclude therefore that although myosin Va has been
shown to be critical in intracellular actin-dependent vesicle
transport in melanocytes and neuroendocrine cells, our data
demonstrate that this motor protein is not required for mouse
platelet granule secretion and other aspects of mouse platelet
function. This contrasts to the important role for Rab27a/b in
platelet dense granule biogenesis and secretion [9–11], and
suggests that Rab27 proteins act through effectors other than
myosin Va. One such effector is Munc13-4, which is essential for
platelet dense granule secretion [27–28]. However, since Munc13-
4-deficient platelets have normal granule numbers [27], there is
likely to be another Rab27 effector that is involved in granule
biogenesis that remains to be described.
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